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Cystic ﬁbrosis (CF) causes airways obstruction and a decline in percent predicted forced expiratory
volume in 1 s (FEV1%). FEV1% is an objective measure of a pulmonary exacerbation of CF; improvement in
FEV1% is the endpoint used often to determine success of treatment of these acute declines in pulmonary
health. Lung Clearance Index (LCI), derived frommultiple breath inert gas washout (MBW) test, measures
ventilation inhomogeneity and small airways dysfunction. In the United States in 2014e2015, enterovirus
D68 (EV-D68), a novel virus, led to hospitalizations in children because of respiratory distress. This report
describes 2 patients with CF admitted for pulmonary exacerbations who were enrolled in an inpatient
study to assess patient satisfaction and utility of MBW to measure LCI. Diagnostic testing indicated that
these patients were infected with EV-D68. Although their FEV1% improved to their previous baseline
following treatment for pulmonary exacerbation, it was discordant with LCI. We discuss LCI as a novel
measure of pulmonary function and hypothesize that, based on these cases, it may be a more sensitive
indicator of ongoing post-viral airways dysfunction as compared to FEV1%.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cystic ﬁbrosis (CF) causes chronic, progressive airways
obstruction. Acute worsening of disease is often accompanied by
increased cough and sputum production, decreased exercise
tolerance and increased obstruction. A decline in percent predicted
forced expiratory volume in 1 s (FEV1%) measured by standard
spirometry is an objective measure of a pulmonary exacerbation of
CF; improvement in FEV1% is the endpoint used often to determine
success of treatment of these acute declines in pulmonary health.
Lung Clearance Index (LCI), derived from multiple breath inert gas
washout test, measures ventilation inhomogeneity and small
airway dysfunction. LCI is calculated as the number of lung volume
turnovers needed to lower the end-tidal tracer gas concentration to
1/40th of the starting concentration1. One of the beneﬁts of LCI is
that measurements are not dependent on age, height or gender,predicted forced expiratory
W, Multiple breath inert gas
t predicted forced expiratory
ymerase chain reaction.
men and Children's Hospital
).
Ltd. This is an open access article uthus percent predicted values are not needed to normalize lung
function to height growth in a disease such as CF that starts in
childhood but progresses throughout life. A value above 6.8 to 7.41
indicates abnormal ventilation distribution [1]. LCI often, but does
not always, inversely correlate, with FEV1% or percent predicted
forced expiratory ﬂow in mid-range (FEF2575%) and it may be
abnormal in young patients whose spirometry is still normal 2. LCI
may be used to measure small airways dysfunction in childrenwith
cystic ﬁbrosis (CF) who may have normal or minimally abnormal
values using standard spirometry and LCI may correlate better with
structural changes than does FEV1% or FEF2575% [1,2]. The tech-
nique is easy to perform even for young children.
In the past decade, outbreaks of several novel respiratory vi-
ruses have been reported and new techniques for identifying vi-
ruses nowenable us to deﬁne a cause of pediatric respiratory illness
in up to 95% of cases [3]. During 2014e2015, many children in the
United States developed acute, severe respiratory illness that was
associated with a new strain of enterovirus (EV-D68). From mid-
August 2014 to January 15, 2015, the Centers for Disease Control
and Prevention or state public health laboratories conﬁrmed a total
of 1153 people in 49 states and the District of Columbia with res-
piratory illness caused by EV-D68; 14 patients who died and had
samples submitted for testing were positive for EV-D68 [4]. Addi-
tionally, there were likely millions of mild EV-D68 infections fornder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Almost all of the conﬁrmed cases were among children, many
whom had asthma or a history of wheezing, and the primary
symptoms were those of lower respiratory tract disease with air-
ways obstruction. Respiratory viral infections can be associated
with long-term decreases in lung function [5]. However, appreci-
ation of short-term effects of viral illness on pulmonary function
may not be recognized using standard spirometry.
We report here the effect of EV-D68 on LCI in two patients with
CF and near-normal spirometry at baseline who were admitted to
the Women and Children's Hospital of Buffalo in 2014.2. Materials and methods
The Institutional Review Board of the University at Buffalo, State
University of New York had previously approved a study exploring
patient satisfaction and utility of LCI compared to spirometry at the
start and completion of inpatient treatment of pulmonary exacer-
bation of CF. The patients in this report provided assent and their
guardians provided informed consent for that study.
Spirometry was performed using Medgraphics equipment. The
technique met or exceeded American Thoracic Society criteria for
reproducibility. Reference values are those recommended by the
Cystic Fibrosis Foundation (Wang et al. method for females 6e15
years for Cases 1 and 2) [6].
Multiple breath washout was performed with the Exhalyzer-D
(Eco Physics, Inc., Ann Arbor, MI). Using this open-circuit system,
subjects breathe room air until baseline nitrogen (N2) concentra-
tion is determined. Carbon dioxide (CO2) is measured using a
mainstream infrared analyzer and oxygen (O2) is measured by side
stream sampling to an internal laser O2 analyzer. FN2 (fraction of
nitrogen) is then calculated using the following formula:
1 ¼ FO2 þ FCO2 þ FN2 þ FAr
FAr (fraction of argon) is treated as a ﬁxed proportion of FN2
during the washout. During the washout phase the tracer gas is
ﬂushed from the lungs by having the subject inhale 100% oxygen
while breathing normally. Respiratory ﬂows and gas concentrations
aremeasured breath-by-breath over time. The study endswhen the
ﬁrst of three consecutive breaths falls below the set nitrogen target
(1/40th of the starting concentration), followed by 5 additional
breaths that fall below that target. LCI is calculated as the cumu-
lative expired volume divided by the functional residual capacity.
The Exhalyzer-D is calibrated each day and is synchronized on a
weekly basis.3. Results
3.1. Case 1
A 12 year old female with CF (F508del/F508del) had baseline
FEV1% predicted at or above 100. In October 2014 she complained ofTable 1
Spirometry and Lung Clearance Index results.
Forced vital capacity (percent
predicted)
Forced expiratory volume in
one second (FEV1) (percent
predicted)
Admission Discharge Admission Discharge
Case 1 2.95 L (95) 3.19 L (102) 2.57 L (93) 2.75 L (100)
Case 2 2.43 L (77) 2.58 L (82) 2.07 L (73) 2.29 L (81)
A change of >10% points in FEV1% is considered to be signiﬁcant.
A signiﬁcant change in LCI has not yet been deﬁned; values above 6.8e7.41 are considechest pain, increased productive cough and dyspnea, and was
found to have a right middle lobe inﬁltrate; her FEV1% predicted
was decreased from baseline of 105 to 93. She was treated as an
inpatient (17 days) with intravenous (IV) colistimethate, mer-
openem and linezolid to cover Pseudomonas aeruginosa and
methicillin-resistant Staphylococcus aureus and intensive airway
clearance, including 7% hypertonic saline and rh-DNAse and chest
vest 4 times per day, along with manual chest physiotherapy to the
right middle lobe. She underwent ﬂexible bronchoscopy which
showed purulent secretions in the RML; these secretions grew EV-
D68 by shell viral culture as well as moderate MRSA and few PA.
Interestingly, her enteroviral RT-PCR from nasopharyngeal secre-
tions at the beginning of the hospitalization was negative. The re-
sults of her spirometry and LCI are shown in the Table 1.
3.2. Case 2
A 15 year old female with CF (F508del/N1303K) had baseline
FEV1% predicted of 80. In October 2014 she presented with cough
and dyspnea with exercise; her FEV1% predicted had decreased
from 80 to 73. She was treated as an inpatient for 10 days with IV
levoﬂoxacin, cefepime and oral minocycline to cover Steno-
trophomonas maltophilia and P. aeruginosa, and intensive airway
clearance, including 7% hypertonic saline and rh-DNAse, and chest
vest 4 times per day. She was found to have enterovirus positive
nasopharyngeal secretions by RT-PCR later conﬁrmed as EV-D68.
The results of her spirometry and LCI are shown in the Table.
4. Discussion
To our knowledge, this is the ﬁrst report of EV-D68 infection and
LCI in patients with CF before and after treatment for pulmonary
exacerbation. During treatment for CF exacerbations, FEV1% pre-
dicted improves in most patients [7]. However, even patients with a
normal or near-normal FEV1% may have ongoing CF lung disease
[8], and this has prompted a search for better measures. Elevated
LCI occurs from asymmetric narrowing of airway lumens due to
inﬂammation, scarring, obstruction by mucus, secondary changes
in airway tone or parenchymal changes in the subtended lung units
resulting in changes in compliance and differing time-constants for
ﬁlling and emptying [1], thus ongoing elevation of LCI despite
improvement in FEV1% may indicate ongoing pathology consistent
with CF airways disease. LCI has the advantages of not exposing
patients to ionizing radiation (as with computed tomography) and
not needing adjustment to predicted normal values for age, height
and gender as with standard spirometry. In the ﬁrst case presented
here, LCI remained markedly elevated despite a return to baseline
normal FEV1% above 100% and increase in FEF2575%. In the second
case, FEV1% and FEF2575% improved to the patient's baseline; LCI
remainedwell above reported normal values. LCI was notmeasured
in these patients at another time point after the end of hospitali-
zation, at a period of further stability. A baseline measurement of
LCI might be helpful in future CF research studies. The result ofForced expiratory ﬂow in mid-range
(FEF2575) (Percent predicted)
Lung Clearance Index
Admission Discharge Admission Discharge
3.31 L/S (101) 3.83 L/S (117) 11.5 12.96
2.38 L/sec (66) 2.91 L/S (81) 12.89 12.03
red abnormal [1].
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supported by a previous study of 63 patients with CF ages 5e19
years, inwhom 42 (67%) had an abnormal LCI despite normal FEV1%
[9]. In a recent meta-analysis of 176 pulmonary exacerbations of CF
in adults and children, LCI signiﬁcantly decreased (was improved)
by 0.40 units or 2.5% following treatment. However, results were
discordant with FEV1 in 42.5% of subjects [10]. Whether these ex-
acerbations were correlated with viral infections is unknown.
Enteroviruses are common pathogens in humans andmay cause
gastrointestinal, respiratory or neurological symptoms. EV-D68 is
uniquely associated with respiratory disease due to the fact that it
grows at 33, the temperature of the upper respiratory tract. EV-
D68 shares some features of rhinoviruses and may shed for up to
3 weeks [4]. Animal and human data suggest that rhinoviral in-
fections may result in an asthma phenotype in a genetically sus-
ceptible host [11]; whether EV-D68 may also have this effect is
unclear. Although there is no seasonal difference in contracting
viral respiratory symptoms in children with CF compared to
matched healthy controls, the duration of symptoms and presence
of lower respiratory tract symptoms is greater in those with CF,
suggesting that viral illnesses contribute additively to the pulmo-
nary dysfunction in these patients [12]. Detection of rhinovirus was
signiﬁcantly associated with the occurrence of an exacerbation in
adults with CF [13]. Earlier studies suggest that both children and
adults with cystic ﬁbrosis have diminished levels of lung function
during symptomatic or asymptomatic viral infections [14]. In the
cases presented here, LCI remained elevated above normal values
(abnormal), although FEV1% and FEF2575%, which had declined from
baseline during acute exacerbation associated with EV-D68,
returned to normal levels after treatment with antibiotics and
intensiﬁed airway clearance. LCI may be a more sensitive indicator
of the impact of viral illness on lung function in patients with CF
than standard spirometry.
5. Conclusion
This case report illustrates the ﬁnding of ongoing airway nar-
rowing and ventilation inhomogeneity after pulmonary exacerba-
tion associated with EV-D68 in two patients with CF that could not
be detected by FEV1% or FEF2575%, but which was demonstrated by
LCI. Although it is still a research tool, LCI may be useful to detect
subtle lung function decline after viral insults.
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